Infant Bacterial Therapeutics Logo

Infant Bacterial Therapeutics

Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.

IBT | ST

Overview

Corporate Details

ISIN(s):
SE0008015242 (+3 more)
LEI:
2138008KVBXCRJGP6Z26
Country:
Sweden
Address:
Bryggargatan 10, 111 21 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Infant Bacterial Therapeutics (IBT) is a clinical-stage pharmaceutical company focused on developing innovative medicines for rare diseases affecting premature infants. The company's primary mission is to prevent necrotizing enterocolitis (NEC), a severe and often fatal inflammatory bowel condition. IBT's lead drug candidate, IBP-9414, is a novel live bacterial therapeutic designed to modulate the infant gut microbiome. IBP-9414, which has received Breakthrough Therapy Designation, is currently being evaluated in a pivotal Phase 3 clinical trial known as 'The Connection Study'. IBT's approach leverages its expertise in using live bacteria as active pharmaceutical substances to address significant unmet medical needs in this vulnerable patient population.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-20 10:35
Board/Management Information
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomina…
English 39.9 KB
2025-10-20 10:35
Board/Management Information
Infant Bacterial Therapeutics AB (publ) meddelar att valberedningen inför årsst…
Swedish 39.6 KB
2025-08-20 08:00
Interim Report
Swedish 586.0 KB
2025-08-20 08:00
Interim Report
English 565.3 KB
2025-05-08 17:45
Post-Annual General Meeting Information
Annual General Meeting of Infant Bacterial Therapeutics
English 41.0 KB
2025-05-08 17:45
Post-Annual General Meeting Information
Årsstämma i Infant Bacterial Therapeutics
Swedish 40.6 KB
2025-05-07 14:30
Quarterly Report
Swedish 550.1 KB
2025-05-07 14:30
Quarterly Report
English 549.5 KB
2025-02-13 08:30
Earnings Release
Swedish 577.8 KB
2025-02-13 08:30
Annual Report
English 571.2 KB
2024-08-28 08:30
Interim Report
Swedish 578.3 KB
2024-08-28 08:30
Interim Report
English 594.7 KB
2024-08-15 16:44
Regulatory News Service
Infant Bacterial Therapeutics patent godkänt i USA
Swedish 48.9 KB
2024-08-15 16:44
Regulatory News Service
Patent for Infant Bacterial Therapeutics has been approved in the USA
English 48.4 KB
2024-07-08 16:40
Regulatory News Service
“The Connection Study” is completed
English 52.7 KB

Automate Your Workflow. Get a real-time feed of all Infant Bacterial Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Infant Bacterial Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Infant Bacterial Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-14 Maria Ekdahl Other Buy 500 17,000.00 SEK
2024-02-08 Anthon Jahreskog Other Buy 839 79,033.80 SEK
2024-02-08 Anthon Jahreskog Other Buy 161 15,134.00 SEK
2023-06-09 Maria Ekdahl Other Buy 1,086 49,956.00 SEK
2023-05-23 Anders Kronström Other Buy 1,329 56,482.50 SEK
2023-05-23 Anthon Jahreskog Other Buy 851 36,593.00 SEK
2023-05-23 Maria Ekdahl Other Buy 465 19,995.00 SEK
2023-05-23 Anthon Jahreskog Other Buy 149 6,377.20 SEK
2023-05-23 Anthon Jahreskog Other Buy 149 6,269.92 SEK
2023-05-22 Maria Ekdahl Other Buy 709 30,487.00 SEK

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.